Literature DB >> 9797243

Comparison of ceftriaxone, amikacin, and ciprofloxacin in treatment of experimental Yersinia enterocolitica O9 infection in mice.

M Jiménez-Valera1, C Gonzalez-Torres, E Moreno, A Ruiz-Bravo.   

Abstract

Ceftriaxone and ciprofloxacin were effective in the treatment of Yersinia enterocolitica O9 intestinal infection in mice. Amikacin was less effective. The impact of these drugs on indigenous bacteria from the intestinal microbiota was studied.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9797243      PMCID： PMC105983     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Yersinia enterocolitica.

Authors:  T L Cover; R C Aber
Journal:  N Engl J Med       Date:  1989-07-06       Impact factor: 91.245

Review 2.  Yersinia enterocolitica: the charisma continues.

Authors:  E J Bottone
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  A simple adult-mouse test for tissue invasiveness in Yersinia enterocolitica strains of low experimental virulence.

Authors:  R Bakour; G Balligand; Y Laroche; G Cornelis; G Wauters
Journal:  J Med Microbiol       Date:  1985-04       Impact factor: 2.472

4.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

5.  Plasmid associated with pathogenicity and calcium dependency of Yersinia enterocolitica.

Authors:  P Gemski; J R Lazere; T Casey
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

6.  In vitro antimicrobial susceptibilities of Yersinia enterocolitica and related species isolated from slaughtered pigs and pork products.

Authors:  J Kwaga; J O Iversen
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

7.  Yersinia enterocolitica isolated from two cohorts of young children in Santiago, Chile: incidence of and lack of correlation between illness and proposed virulence factors.

Authors:  J G Morris; V Prado; C Ferreccio; R M Robins-Browne; A M Bordun; M Cayazzo; B A Kay; M M Levine
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

8.  Simple method for demonstration of differential colony morphology of plasmid-associated virulent clones of Yersinia enterocolitica.

Authors:  D Mazigh; J M Alonso; H H Mollaret
Journal:  J Clin Microbiol       Date:  1983-03       Impact factor: 5.948

9.  The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile.

Authors:  N S Ambrose; M Johnson; D W Burdon; M R Keighley
Journal:  J Antimicrob Chemother       Date:  1985-03       Impact factor: 5.790

10.  Immunomodulation in mice by experimental infection with Yersinia enterocolitica.

Authors:  A Ruiz-Bravo; M Jimenez-Valera; G Alvarez de Cienfuegos; C Ruiz; K Kouwatli; A Ramos-Cormenzana
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955
View more
  3 in total

1.  Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.

Authors:  Kathrin Endt; Lisa Maier; Rina Käppeli; Manja Barthel; Benjamin Misselwitz; Marcus Kremer; Wolf-Dietrich Hardt
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

2.  Prudent Antimicrobial Use Is Essential to Prevent the Emergence of Antimicrobial Resistance in Yersinia enterocolitica 4/O:3 Strains in Pigs.

Authors:  Juho Koskinen; Pilar Ortiz-Martínez; Riikka Keto-Timonen; Suvi Joutsen; Maria Fredriksson-Ahomaa; Hannu Korkeala
Journal:  Front Microbiol       Date:  2022-03-10       Impact factor: 5.640

Review 3.  Severe acute diarrhea.

Authors:  Julia I Gore; Christina Surawicz
Journal:  Gastroenterol Clin North Am       Date:  2003-12       Impact factor: 3.806
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.